
Jakub Tomala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5418101/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pertussis toxin suppresses dendritic cell-mediated delivery of B. pertussis into lung-draining lymph nodes. PLoS Pathogens, 2022, 18, e1010577.	4.7	5
2	Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling. Journal of Controlled Release, 2021, 332, 563-580.	9.9	11
3	IL-7/αIL-7 mAb M25 immunocomplexes expand CD8+ T cells but paradoxically abrogate the antitumor activity of CTLA-4 and PD-1 blockage. Cytokine, 2020, 133, 155174.	3.2	3
4	Characterization of Immune Cell Subset Expansion in Response to Therapeutic Treatment in Mice. Methods in Molecular Biology, 2020, 2111, 101-114.	0.9	2
5	Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. Journal of Immunology, 2018, 201, 2094-2106.	0.8	58
6	Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells. Oncolmmunology, 2017, 6, e1311433.	4.6	47
7	Cyclic AMP-Elevating Capacity of Adenylate Cyclase Toxin-Hemolysin Is Sufficient for Lung Infection but Not for Full Virulence of Bordetella pertussis. Infection and Immunity, 2017, 85, .	2.2	31
8	The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel. Journal of Controlled Release, 2017, 246, 1-11.	9.9	27
9	Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate. Biomaterials, 2017, 115, 65-80.	11.4	43
10	Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. Oncolmmunology, 2017, 6, e1258505.	4.6	30
11	IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?. Oncolmmunology, 2016, 5, e1102829.	4.6	19
12	The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia. Journal of Controlled Release, 2016, 223, 1-10.	9.9	38
13	Poreâ€formation by adenylate cyclase toxoid activates dendritic cells to prime CD8 + and CD4 + T cells. Immunology and Cell Biology, 2016, 94, 322-333.	2.3	19
14	Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms. Immunity, 2015, 42, 815-825.	14.3	191
15	Novel IL-2-Poly(HPMA)Nanoconjugate Based Immunotherapy. Journal of Biomedical Nanotechnology, 2015, 11, 1662-1673.	1.1	12
16	Bordetella Adenylate Cyclase Toxin Differentially Modulates Toll-Like Receptor-Stimulated Activation, Migration and T Cell Stimulatory Capacity of Dendritic Cells. PLoS ONE, 2014, 9, e104064.	2.5	22
17	Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera. Immunology Letters, 2014, 159, 1-10.	2.5	29
18	Chimera of IL-2 Linked to Light Chain of anti-IL-2 mAb Mimics IL-2/anti-IL-2 mAb Complexes Both Structurally and Functionally. ACS Chemical Biology, 2013, 8, 871-876.	3.4	18

Jakub Tomala

#	Article	IF	CITATIONS
19	Delivery of Large Heterologous Polypeptides across the Cytoplasmic Membrane of Antigen-Presenting Cells by the Bordetella RTX Hemolysin Moiety Lacking the Adenylyl Cyclase Domain. Infection and Immunity, 2012, 80, 1181-1192.	2.2	23
20	Synergistic effect of EMF–BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma. Journal of Drug Targeting, 2011, 19, 890-899.	4.4	11
21	Antitumor activity of ILâ€2/antiâ€ILâ€2 mAb immunocomplexes exerts synergism with that of <i>N</i> â€(2â€hydroxypropyl)methacrylamide copolymerâ€bound doxorubicin conjugate due to its low immunosuppressive activity. International Journal of Cancer, 2011, 129, 2002-2012.	5.1	9
22	In Vivo Expansion of Activated Naive CD8+ T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer Immunotherapy. Journal of Immunology, 2009, 183, 4904-4912.	0.8	84
23	Overcoming Immunoescape Mechanisms of BCL1 Leukemia and Induction of CD8+ T-Cell–Mediated BCL1-Specific Resistance in Mice Cured by Targeted Polymer-Bound Doxorubicin. Cancer Research, 2008, 68, 9875-9883.	0.9	13